Advanced search
Publication Cover
Drug Delivery Volume 28, 2021 - Issue 1
Submit an article Journal homepage
5,020
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

Wenhai Fua Department of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Wenjun Heb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaCorrespondence[email protected]
View further author information
,
Yuexin Lia Department of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Yangxiao Chena Department of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Jingyi Liangb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Hui Leib Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Lin Fua Department of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, ChinaView further author information
,
Yanghang Chenb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Ni Renb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Qian Jiangb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Yi Shenb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Ran Mab Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Tao Wangb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Xinni Wangb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Nuofu Zhangb Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
,
Dakai Xiaob Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaView further author information
&
Chunli Liub Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1007-1019 | Received 23 Feb 2021, Accepted 04 May 2021, Published online: 01 Jun 2021

References

  • Apitz C , Schranz D. (2018). Sildenafil-Bosentan drug-drug interaction: a word of caution regarding the most common combination therapy in children with advanced pulmonary arterial hypertension.Respiration 96:302.
  • Ataya A , Cope J , Alnuaimat H. (2016). A review of targeted pulmonary arterial hypertension-specific pharmacotherapy.J Clin Med 5:114.
  • Badesch D , Bodin F , Channick R ,et al. (2002). Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension.Curr Ther Res 63:227–46.
  • Badesch DB. (2000). Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.Ann Intern Med 6:425–34.
  • Barst RJ , McGoon M , McLaughlin V , Tapson V , Oudiz R , Shapiro S , Beraprost Study Group,et al. (2003). Beraprost therapy for pulmonary arterial hypertension.J Am Coll Cardiol 41:2119–25.
  • Barst RJ , Oudiz RJ , Beardsworth A , Brundage BH , Simonneau G , Ghofrani HA ,Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group,et al. (2011). Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.J Heart Lung Transplant 30:632–43.
  • Barst RJ , Rubin LJ , Long WA ,et al. (1996). A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.N Engl J Med 334:296–301.
  • Barst RJ. (1997). Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin.Heart 4:299–301.
  • Baughman RP , Culver DA , Cordova FC ,et al. (2014). Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.Chest 145:810–7.
  • Bennouna J , Moreno Vera SR. (2016). Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.Future Oncol 12:355–72.
  • Bermejo J , Yotti R , Garcia-Orta R , Sanchez-Fernandez PL , Castano M , Segovia-Cubero J , Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators,et al. (2018). Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.Eur Heart J 39:1255–64.
  • Burks M , Stickel S , Galie N. (2018). Pulmonary arterial hypertension: combination therapy in practice.Am J Cardiovasc Drugs 18:249–57.
  • Burnett H , Earley A , Voors AA ,et al. (2017). Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis.Circ Heart Fail 10:e003529.
  • Cheitlin MD. (2006). Sildenafil citrate therapy for pulmonary arterial hypertension.Yearbook Cardiol 2006:392–3.
  • Coghlan JG , Channick R , Chin K ,et al. (2018). Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study.Am J Cardiovasc Drugs 18:37–47.
  • D’Alto M , Badagliacca R , Argiento P ,et al. (2020). Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension.Chest 157:376–83.
  • D’Alto M , Romeo E , Argiento P ,et al. (2018). Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).J Cardiovasc Med (Hagerstown) 19:12–7.
  • De-Zhen Z , An-Meng WEI. (2020). Effect of Bosentan combined with tadalafil on activity endurance and cardiac function in patients with pulmonary hypertension.Chinese Journal for Clinicians 48:566–9.
  • Dodson MW , Brown LM , Elliott CG. (2018). Pulmonary arterial hypertension.Heart Fail Clin 14:255–69.
  • Galie N , Barbera JA , Frost AE ,et al. (2015). Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.N Engl J Med 373:834–44.
  • Galie N , , Beghetti M , Gatzoulis MA , Granton J , Berger RM , Lauer A ,et al.;Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators . (2006). Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.Circulation 114:48–54.
  • Galie N , Brundage BH , Ghofrani HA ,et al. (2009). Tadalafil therapy for pulmonary arterial hypertension.Circulation 119:2894–903.
  • Galiè N , Humbert M , Vachiéry J-L , Vizza C , Kneussl M , Manes A , Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group,et al. (2002). Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.J Am Coll Cardiol 39:1496–502.
  • Galiè N , Rubin LJ , Hoeper MM ,et al. (2008). Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.The Lancet 371:2093–100.
  • Galiè N , Müller K , Scalise A-V , Grünig E. (2015). PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.Eur Respir J 45:1314–22.
  • Galiè N , Olschewski H , Oudiz RJ ,et al. (2008). Ambrisentan for the treatment of pulmonary arterial hypertension.Circulation 117:3010–9.
  • Gao XF , Zhang JJ , Jiang XM , Ge Z ,et al. (2017). Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.PPA 11:871–85.
  • Gatzoulis MA , , Landzberg M , Beghetti M , Berger RM , Efficace M , Gesang S , MAESTRO Study Investigators,et al. (2019). Evaluation of macitentan in patients with eisenmenger syndrome.Circulation 139:51–63.
  • Ghofrani HA , Galie N , Grimminger F ,et al. (2013). Riociguat for the treatment of pulmonary arterial hypertension.N Engl J Med 369:330–40.
  • Grünig E , Ohnesorge J , Benjamin N ,et al. (2017). Plasma drug concentrations in patients with pulmonary arterial hypertension on combination treatment.Respiration 94:26–37.
  • Han X , Zhang Y , Dong L ,et al. (2017). Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost.Respir Care 62:489–96.
  • Hassoun PM , Zamanian RT , Damico R ,et al. (2015). Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension.Am J Respir Crit Care Med 192:1102–10.
  • Hiremath J , Thanikachalam S , Parikh K , Shanmugasundaram S , Bangera S , Shapiro L , TRUST Study Group,et al. (2010). Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.J Heart Lung Transplant 29:137–49.
  • Hoeper MM , Leuchte H , Halank M ,et al. (2006). Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.Eur Respir J 28:691–4.
  • Hozo SP , Djulbegovic B , Hozo I. (2005). Estimating the mean and variance from the median, range, and the size of a sample.BMC Med Res Methodol 5:13.
  • Humbert M , Barst RJ , Robbins IM ,et al. (2004). Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.Eur Respir J 24:353–9.
  • Humbert M , Coghlan JG , Ghofrani H-A ,et al. (2017). Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.Ann Rheum Dis 76:422–6.
  • Iversen K , Jensen AS , Jensen TV ,et al. (2010). Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.Eur Heart J 31:1124–31.
  • Jain S , Khera R , Girotra S ,et al. (2017). Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis.Chest 151:90–105.
  • Jansa P , Pulido T. (2018). Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the seraphin trial.Am J Cardiovasc Drugs 18:1–11.
  • Jian-Yong ZHU , Yu-Qin ZENG , Qing HU ,et al. (2018). Clinical effect of sildenafil combined with Bosentan in treatment of connective tissue disease associated moderate-severe pulmonary arterial hypertension.Chin J Respir Critic Care Med 17:369–72.
  • Jian-zhou GUO , Yan-yan MA , Zhi-wei WANG. (2018). Clinical effect and changes of cardiac function in patients with pulmonary hypertension after operation of congenital heart disease applicating tadalafil combined with Bosentan.South China J Cardiovasc Dis 24:40.
  • Jing ZC , Parikh K , Pulido T ,et al. (2013). Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.Circulation 127:624–33.
  • Jing ZC , Yu ZX , Shen JY ,et al. (2011). Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.Am J Respir Crit Care Med 183:1723–9.
  • Kusunose K , Yamada H , Nishio S ,et al. (2019). Pulmonary artery hypertension-specific therapy improves exercise tolerance and outcomes in exercise-induced pulmonary hypertension.JACC Cardiovasc Imaging 12:2576–9.
  • Kuwana M , Blair C , Takahashi T ,et al. (2020). Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.Ann Rheum Dis 79:626–34.
  • Lajoie AC , Lauziere G , Lega JC ,et al. (2016). Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.Lancet Respir Med 4:291–305.
  • Lin H , Wang M , Yu Y ,et al. (2018). Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: a network meta-analysis.Pulm Pharmacol Ther 50:1–10.
  • ling-Yun AI , Chen GUO , Yan DING ,et al. (2016). CliIIical observation of Bosentan combined with Sildenafil in the treatment of congenital heart disease with severe pulmonary arterial hypertension.China Modern Med 23:112–4.
  • Mbuagbaw L , Rochwerg B , Jaeschke R ,et al. (2017). Approaches to interpreting and choosing the best treatments in network meta-analyses.Syst Rev 6:79.
  • McLaughlin VV , Benza RL , Rubin LJ ,et al. (2010). Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.J Am Coll Cardiol 55:1915–22.
  • McLaughlin V , Channick RN , Ghofrani HA ,et al. (2015). Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.Eur Respir J 46:405–13.
  • McLaughlin VV , Oudiz RJ , Frost A ,et al. (2006). Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.Am J Respir Crit Care Med 174:1257–63.
  • Montani D , Chaumais MC , Guignabert C ,et al. (2014). Targeted therapies in pulmonary arterial hypertension.Pharmacol Ther 141:172–91.
  • Ni AI , Wa ER. (2018). To investigate the clinical effect of Bosentan in the treatment of patients with congenital heart disease complicated with pulmonary hypertension.China Health Care Nutr 28:187–6.
  • O'Connell C , O'Callaghan DS , Humbert M. (2013). Novel medical therapies for pulmonary arterial hypertension.Clin Chest Med 34:867–80.
  • Paz MA , de-La-Sierra A , Saez M ,et al. (2016). Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement.Medicine (Baltimore) 95:e4071 )
  • Petrovic M , Locatelli I. (2020). Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.J Comp Eff Res 9:7–22.
  • Prins KW , Thenappan T. (2016). World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology.Cardiol Clin 34:363–74.
  • Pulido T , Adzerikho I , Channick RN ,et al. (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension.N Engl J Med 369:809–18.
  • Qin LUO , Zhi-Hong LIU. (2020). Principles and progress of targeted drug therapy for pulmonary hypertension.Chin Circul J 35:611–4.
  • Querejeta Roca G , Campbell P , Claggett B ,et al. (2015). Right atrial function in pulmonary arterial hypertension.Circ Cardiovasc Imaging 8:e003521.
  • Ronald JO. (2004). Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.Chest 2:420–7.
  • Rosenkranz S , Ghofrani H-A , Beghetti M ,et al. (2015). Riociguat for pulmonary arterial hypertension associated with congenital heart disease.Heart 101:1792–9.
  • Rubin LJ , Badesch DB , Barst RJ ,et al. (2002). Bosentan therapy for pulmonary arterial hypertension.N Engl J Med 346:896–903.
  • Rubin LJ , Galie N , Grimminger F ,et al. (2015). Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).Eur Respir J 45:1303–13.
  • Salanti G , Ades AE , Ioannidis JPA. (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.J Clin Epidemiol 64:163–71.
  • Simonneau G , Rubin LJ , Galie N ,et al. (2014). Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.J Heart Lung Transplant 33:689–97.
  • Simonneau G , Torbicki A , Hoeper MM ,et al. (2012). Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.Eur Respir J 40:874–80.
  • Sitbon O , Bosch J , Cottreel E ,et al. (2019). Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.Lancet Respir Med 7:594–604.
  • Sitbon O , Channick R , Chin KM ,et al. (2015). Selexipag for the treatment of pulmonary arterial hypertension.N Engl J Med 373:2522–33.
  • Spradley CD. (2012). Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.Yearbook Pulmon Dis 2012:124–125.
  • Tapson VF , Jing ZC , Xu KF , Pan L , Feldman J , Kiely DG , FREEDOM-C2 Study Team,et al. (2013). Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.Chest 144:952–8.
  • Tapson VF , Torres F , Kermeen F ,et al. (2012). Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.Chest 142:1383–90.
  • Vizza CD , Jansa P , Teal S ,et al. (2017). Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.BMC Cardiovasc Disord 17:239.
  • Wan X , Wang W , Liu J , Tong T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.BMC Med Res Methodol 14:135.
  • Wang Y-B , Cui Y-X , Song J-N ,et al. (2018). Efficacies of various surgical regimens in the treatment of renal calculi patients: a network meta-analysis in 25 enrolled controlled clinical trials.Kidney Blood Press Res 43:1183–98.
  • Wang S , Yu M , Zheng X , Dong S. (2018). A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.Drug Deliv 25:1898–909.
  • Wei A , Gu Z , Li J ,et al. (2016). Clinical adverse effects of endothelin receptor antagonists: insights from the meta‐analysis of 4894 patients from 24 randomized double‐blind placebo‐controlled clinical trials.JAHA 5:.
  • White RJ , Jerjes-Sanchez C , Bohns Meyer GM , Pulido T , Sepulveda P , Wang KY , FREEDOM-EV Investigators,et al. (2020). Combination therapy with oral treprostinil for pulmonary arterial hypertension. a double-blind placebo-controlled clinical trial.Am J Respir Crit Care Med 201:707–17.
  • White RJ , Vonk-Noordegraaf A , Rosenkranz S ,et al. (2019). Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.Respir Res 20:208.
  • Wilkins MR , Paul GA , Strange JW ,et al. (2005). Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study.Am J Respir Crit Care Med 171:1292–7.
  • Zhang X-H , Xiao C. (2018). Diagnostic value of nineteen different imaging methods for patients with breast cancer: a network meta-analysis.Cell Physiol Biochem 46:2041–55.
  • Zheng YG , Ma H , Chen L ,et al. (2018). Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials.Pulm Circ 8:2045894018798183.
  • Zhuang Y , Jiang B , Gao H , Zhao W. (2014). Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.Hypertens Res 37:507–12.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.